On Saturday June 17, 2006, six prostate cancer specialists participated
in a “spirited” discussion regarding treatment options
for patients with hormone refractory and advanced prostate cancer.
The meeting was produced by PCRI and underwritten by an educational
grant from Abbott Oncology. It was held at the Hyatt Regency O’Hare
and included twenty-one patients and six partners from the Chicago
area and several diverse locations like: Waleska, GA, Cooperstown,
NY and Boise, ID. PCRI’s Program Director, Harry Pinchot moderated
the session by asking questions submitted by the attendees to the
panel of five medical oncologists and one urologist:
Oliver Sartor, MD, Dana-Farber Cancer Institute, Boston
Charles Myers, MD, American Institute of Diseases of the Prostate,
Free Union, VA
Steven Tucker, MD, The Angeles Clinic, Santa Monica, CA
Nicholas Vogelzang, MD, Nevada Cancer Institute, Las Vegas
Daniel Shevrin, MD, Evanston Northwestern Health Care, Evanston, IL
Gerald W Chodak, MD, Midwest Prostate and Urology Health Center, Chicago
The questions were grouped under the general topics: Second-line
Treatments, Chemotherapy, Bone Strengthening, Novel Agents and Quality
of Life Issues. Of the many comments worth noting:
“ If we could completely eliminate androgen, we could keep
more patients from developing hormone refractory prostate cancer
(HRPC). Most PC
still needs the androgen receptor. In breast cancer, there are
ways to fully degrade the estrogen receptor”
“ There does not appear to be a major detriment to the use of intermittent
androgen deprivation therapy, (in patients who achieve an undetectable
PSA nadir)”
“ Some patients with a fast PSA doubling time and Gleason 9-10 can be
put into remission if Taxotere is started early”
“ For HRPC, first line therapy should be a clinical trial involving Taxotere
plus one of many interesting novel agents”
“
In lung cancer, four cycles of chemotherapy is as effective as more
but we don’t have data for prostate cancer”
“
With chemotherapy, supportive care matters ‘big time’,
the heart of medical oncology is poison control”
Attendees had an opportunity for individual discussions with the panel
and PCRI representatives during the continental breakfast, morning
break, and luncheon.
The meeting drew high marks and many favorable comments
including: “I
am in total in “AWE” to be in the same room with these
doctors who I believe are truly “Saints” in the world
of cancer.” and “Excellent dialog between physicians
with markedly different approaches to this disease”.
The meeting was video taped and you can also request a set of the
DVDs by submitting
a request online or calling
our Los Angeles office at 310-743-2110.